• HCW Biologics will present preclinical HCW11-040 data Nov. 7, 2026, at the Society for Immunotherapy of Cancer meeting in Phoenix.
• The experimental cancer treatment outperformed pembrolizumab in rejuvenating exhausted T cells against human cancer cells, with comparable immune checkpoint-blocking activity.
• Its mouse counterpart, HCW11-050, showed stronger activity against immunologically cold solid tumors than immune checkpoint inhibitors in preclinical models.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611061100PRIMZONEFULLFEED9871962) on November 06, 2026, and is solely responsible for the information contained therein.